High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.

@article{Ager1996HighdoseCE,
  title={High-dose carmustine, etoposide and melphalan ('BEM') with autologous stem cell transplantation: a dose-toxicity study.},
  author={Shellee J. Ager and Premini Mahendra and Edward M. Richards and Gary Jonathan Bass and Trevor P Baglin and Robert E. Marcus},
  journal={Bone marrow transplantation},
  year={1996},
  volume={17 3},
  pages={
          335-40
        }
}
We have investigated the toxicity of dose-escalation of BCNU, etoposide and melphalan ('BEM') chemotherapy with autologous stem cell transplantation in patients with haematological malignancies. Seventy-two patients with haematological malignancies were treated with BCNU (600 mg/m2, 450 mg/m2 or 300 mg/m2), etoposide 2 g/m2 and melphalan 140 mg/m2 followed by autologous bone marrow transplantation (ABMT), n = 51, or autologous peripheral blood progenitor cell transplantation (APBPCT), n = 21… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

High-dose etoposide in allogeneic stem cell transplantation

  • Cancer Chemotherapy and Pharmacology
  • 2012
VIEW 1 EXCERPT
CITES BACKGROUND